Journal of Alzheimer's Disease achieves significant impact factor

July 13, 2007

International publisher IOS Press and the Editorial Board of the Journal of Alzheimer's Disease (JAD) are proud to announce that the journal has achieved a 3.058 Impact Factor the first year that a rating has been assigned to this title. This is significantly higher than the only other journal devoted solely to Alzheimer's disease (AD) research indexed in Thomson Scientific's Journal Citation Reports 2006.

Editors-in-Chief George Perry and Mark A. Smith commented, "We are extremely pleased to have quantitative evidence of the high regard in which the Journal of Alzheimer's Disease is held by researchers and clinicians working in AD and the extent to which JAD's articles are cited throughout the medical and scientific literature. The dedication of the entire editorial board, contributing authors and our publisher, IOS Press, has certainly contributed to the success of the journal."

"The Journal of Alzheimer's Disease is one of our flagship publications," stated Einar Fredriksson, Director of IOS Press. "As publisher, one of our primary goals is to provide an open forum for original research that will expedite the fundamental understanding of Alzheimer's disease. It is particularly gratifying to see the impact that this journal is having in the field. As the Journal of Alzheimer's Disease continues to grow and flourish, future plans include increasing to 12 issues in 2008 and the inclusion of a Review Article section under the editorial guidance of Ralph N. Martins of the Edith Cowan University, Perth, Australia."
-end-
The Journal of Alzheimer's Disease is an international multidisciplinary journal to facilitate progress in understanding the etiology, pathogenesis, epidemiology, genetics, behavior, treatment and psychology of Alzheimer's disease. The journal publishes research reports, reviews, short communications, book reviews, and letters-to-the-editor. Groundbreaking research that has appeared in the journal includes novel therapeutic targets, mechanisms of disease and clinical trial outcomes.

About IOS Press

Celebrating its 20th anniversary, IOS Press is a rapidly expanding scientific, technical, medical and professional publishing house focusing on a broad range of subject areas. Headquartered in Amsterdam, IOS Press publishes approximately 150 new books each year, including Delft University Press titles, and 85 international journals, covering topics ranging from computer science and mathematics to medicine and the natural sciences. Electronic access to all journals and most book series is now available. IOS Press also maintains offices in the Washington, DC area and Berlin as well as a co-publishing relationship with Ohmsha, Ltd (Tokyo).

University of Texas at San Antonio

Related Disease Articles from Brightsurf:

CLCN6 identified as disease gene for a severe form of lysosomal neurodegenerative disease
A mutation in the CLCN6 gene is associated with a novel, particularly severe neurodegenerative disorder.

Cellular pathway of genetic heart disease similar to neurodegenerative disease
Research on a genetic heart disease has uncovered a new and unexpected mechanism for heart failure.

Mechanism linking gum disease to heart disease, other inflammatory conditions discovered
The link between periodontal (gum) disease and other inflammatory conditions such as heart disease and diabetes has long been established, but the mechanism behind that association has, until now, remained a mystery.

Potential link for Alzheimer's disease and common brain disease that mimics its symptoms
A new study by investigators from Brigham and Women's Hospital uncovered a group of closely related genes that may capture molecular links between Alzheimer's disease and Limbic-predominant Age-related TDP-43 Encephalopathy, or LATE, a recently recognized common brain disorder that can mimic Alzheimer's symptoms.

Antioxidant agent may prevent chronic kidney disease and Parkinson's disease
Researchers from Osaka University developed a novel dietary silicon-based antioxidant agent with renoprotective and neuroprotective effects.

Tools used to study human disease reveal coral disease risk factors
In a study published in Scientific Reports, a team of international researchers led by University of Hawai'i (UH) at Mānoa postdoctoral fellow Jamie Caldwell used a statistical technique typically employed in human epidemiology to determine the ecological risk factors affecting the prevalence of two coral diseases--growth anomalies, abnormalities like coral tumors, and white syndromes, infectious diseases similar to flesh eating bacteria.

Disease-aggravating mutation found in a mouse model of neonatal mitochondrial disease
The new mitochondrial DNA (mtDNA) variant drastically speeds up the disease progression in a mouse model of GRACILE syndrome.

Human longevity largest study of its kind shows early detection of disease & disease risks
Human Longevity, Inc. (HLI) announced the publication of a ground-breaking study in the journal Proceedings of the National Academy of Sciences (PNAS).

30-year study identifies need of disease-modifying therapies for maple syrup urine disease
A new study analyzes 30 years of patient data and details the clinical course of 184 individuals with genetically diverse forms of Maple Syrup Urine Disease (MSUD), which is among the most volatile and dangerous inherited metabolic disorders.

Long-dormant disease becomes most dominant foliar disease in New York onion crops
Until recently, Stemphylium leaf blight has been considered a minor foliar disease as it has not done much damage in New York since the early 1990s.

Read More: Disease News and Disease Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.